Journal of diabetes and its complications最新文献

{"title":"Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis","authors":"Maria-Ioanna Stefanou ,&nbsp;Anastasios Tentolouris ,&nbsp;Evangelos Panagiotopoulos ,&nbsp;Aikaterini Theodorou ,&nbsp;Annerose Mengel ,&nbsp;Athanasia Athanasaki ,&nbsp;Vaia Lambadiari ,&nbsp;Melpomeni Peppa ,&nbsp;Marianna Papadopoulou ,&nbsp;Georgios P. Paraskevas ,&nbsp;Sotirios Giannopoulos ,&nbsp;Gerasimos Siasos ,&nbsp;Vijay K. Sharma ,&nbsp;Ulf Ziemann ,&nbsp;Georgios Tsivgoulis","doi":"10.1016/j.jdiacomp.2026.109271","DOIUrl":"10.1016/j.jdiacomp.2026.109271","url":null,"abstract":"<div><h3>Background and aims</h3><div>Vascular dementia (VaD) is strongly associated with type 2 diabetes (T2DM), overweight, and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular risk and exhibit neuroprotective properties, yet their effects in incident VaD remain uncertain. This study evaluated whether GLP-1 RAs have preventive potential for VaD in adults with T2DM, overweight, or obesity.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis of randomized-controlled clinical trials (RCTs) was conducted to estimate the risk of incident VaD among patients with T2DM or overweight/obesity treated with GLP-1 RAs versus placebo. Data were pooled using a random-effects model, with outcomes expressed as risk ratios (RRs) and 95% confidence intervals (CIs). Subgroup analysis was performed after stratification by population type (T2DM vs. overweight/obesity), and meta-regression assessed the association between RCT duration and effect size.</div></div><div><h3>Results</h3><div>Seven RCTs (six in T2DM, one in overweight/obesity) comprising 61,610 participants were included. GLP-1 RA treatment was not associated with a statistically significant difference in VaD incidence (RR: 0.50; 95% CI: 0.19–1.32; I² = 0%). Subgroup analysis revealed no significant between-group differences (p for subgroups = 0.612), although numerically lower VaD rates were observed in the T2DM subgroup (RR: 0.38; 95% CI: 0.13–1.11). Meta-regression did not demonstrate a significant association between follow-up duration and treatment effect (β = −0.291; SE = 0.212; 95% CI: −0.843 to 0.262; p = 0.229).</div></div><div><h3>Conclusions</h3><div>The pooled evidence did not confirm a statistically significant reduction in VaD risk with GLP-1 RA therapy. Numerically lower VaD incidence in T2DM populations warrants further investigation in adequately powered and systematically adjudicated trials.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 3","pages":"Article 109271"},"PeriodicalIF":3.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146075133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?” [JDC, volume 39, issue 10, October 2025, 109132]","authors":"Maria Aurora Roma-Wilson ,&nbsp;Paolo Pozzilli","doi":"10.1016/j.jdiacomp.2025.109229","DOIUrl":"10.1016/j.jdiacomp.2025.109229","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 3","pages":"Article 109229"},"PeriodicalIF":3.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146189609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(26)00026-7","DOIUrl":"10.1016/S1056-8727(26)00026-7","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 3","pages":"Article 109281"},"PeriodicalIF":3.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146189610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking diabetic foot ulcer care: Integrating exercise and physical activity","authors":"Jane E. Nakamura ,&nbsp;Angela J. Fong ,&nbsp;Abbi D. Lane ,&nbsp;Michael E. Munson ,&nbsp;Brian M. Schmidt ,&nbsp;Crystal M. Holmes ,&nbsp;Jacob M. Haus","doi":"10.1016/j.jdiacomp.2025.109252","DOIUrl":"10.1016/j.jdiacomp.2025.109252","url":null,"abstract":"<div><div>Because repetitive trauma and pressure contributes to diabetic foot ulcer (DFU) development and progression, offloading is one of the main therapies used in treatment. The term offloading has become conflated with a reduction in movement altogether, increasing sedentary time and, with it, the risk of associated adverse health outcomes. The aim of this narrative review is to evaluate the literature on movement-based interventions (reducing sedentary time, increasing physical activity (PA), or increasing exercise) in DFU patients. We found 16 articles that looked at the effect of exercise in individuals with a DFU. While many studies demonstrate the therapeutic potential of exercise, methodological inconsistencies between them prevent firm conclusions from being drawn regarding the efficacy of movement in promoting ulcer healing. The collected evidence underscores the need to address factors such as patient adherence, weight-bearing progression, and specifics surrounding movement programs (frequency, intensity, etc.) in future studies. Addressing these gaps, as well as determining barriers and facilitators to engaging in movement unique to those with a DFU, will advance research rigor and, with it, our understanding of how movement can be effectively leveraged to improve DFU care.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 2","pages":"Article 109252"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145819330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking HbA1c and white blood cell counts to the development of diabetic macular edema in type 2 diabetes: A systematic review and meta-analysis","authors":"Linh Khanh Do ,&nbsp;Charisse Yu-Jean Kuo ,&nbsp;Stuti Lonie Misra ,&nbsp;Rinki Murphy ,&nbsp;Odunayo Omolola Mugisho","doi":"10.1016/j.jdiacomp.2025.109237","DOIUrl":"10.1016/j.jdiacomp.2025.109237","url":null,"abstract":"<div><h3>Aim</h3><div>To investigate the association between HbA1c and white blood cell (WBC) counts with diabetic macular edema (DME) in type 2 diabetes (T2DM).</div></div><div><h3>Methods</h3><div>The study was registered on PROSPERO (registration number: CRD42024523016). A comprehensive literature search was conducted on PubMed and EMBASE up to May 2024, including studies investigating HbA1c and WBC counts in patients with T2DM, with and without DME. Standardized mean differences (SMD) and odds ratios (OR) with 95 % confidence intervals (CI) were calculated. A random-effects model was used to pool data. Risk of bias was evaluated using the Newcastle-Ottawa Scale.</div></div><div><h3>Results</h3><div>Forty-eight studies involving 207,536 participants were included. Egger's test indicated a significant publication bias among studies reporting HbA1c as OR 95 %CI. Pooled results showed that higher HbA1c may increase DME risk (SMD = 0.29, 95 %CI: 0.17 to 0.41; OR = 1.32, 95 %CI: 1.19 to 1.48). Although the same cohort, subgroup analyses found no associations between HbA1c and center-involved DME (SMD = 0.3, 95 %CI: -0.08 to 0.53) or DME development in severe non-proliferative diabetic retinopathy (NPDR)/PDR (SMD = -0.14, 95 %CI: -0.37 to 0.09). In contrast, lower lymphocyte count was significantly associated with DME (SMD = -0.24, 95 %CI: -0.45 to -0.03).</div></div><div><h3>Conclusions</h3><div>Higher HbA1c and lower lymphocyte count may increase DME risk in T2DM, suggesting potential roles of hyperglycemia and systemic inflammation in its etiology. However, substantial heterogeneity and publication bias warrant cautious interpretation. Future research should clarify the causal role of systemic inflammation through longitudinal studies and investigate DME across different DR stages and diagnostic criteria.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 2","pages":"Article 109237"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of high estimated glomerular filtration rate on kidney prognosis in individuals with type 2 diabetes","authors":"Ko Hanai ,&nbsp;Yurika Yamashige ,&nbsp;Tomomi Mori ,&nbsp;Yui Yamamoto ,&nbsp;Hidekazu Murata ,&nbsp;Tomohiro Shinozaki ,&nbsp;Tomoko Nakagami","doi":"10.1016/j.jdiacomp.2025.109255","DOIUrl":"10.1016/j.jdiacomp.2025.109255","url":null,"abstract":"<div><h3>Aims</h3><div>To clarify the effects of high glomerular filtration rate (GFR) at baseline on subsequent kidney failure in diabetes.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study including 8369 individuals with type 2 diabetes. The exposure was baseline estimated GFR (eGFR), treated both as a categorical variable (with seven categories: ≥105, 90–105, 75–90, 60–75, 45–60, 30–45, and &lt;30 mL/min/1.73 m²) and as a continuous variable. The outcome was a composite of a ≥40 % eGFR decrease or the kidney-replacement therapy initiation. We estimated the hazard ratios using a multivariable Cox proportional hazards model.</div></div><div><h3>Results</h3><div>Individuals with eGFR of ≥90 mL/min/1.73 m² as well as those with eGFR of &lt;60 mL/min/1.73 m² significantly had higher outcome hazards than those with eGFR of 60–75 mL/min/1.73 m². The spline model exhibited a similar trend. When classifying individuals into three groups based on baseline urinary albumin-to-creatinine ratio (UACR) of &lt;10, 10–30 or ≥30 mg/g, the outcome hazard of those with eGFR of ≥90 mL/min/1.73 m² increased as baseline UACR decreased, with a significant interaction (<em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>A high eGFR was a risk factor for kidney failure in individuals with type 2 diabetes. The lower the baseline UACR level, the stronger this association.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 2","pages":"Article 109255"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145878492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of atherogenic index of plasma baselines and trajectories with the progression from prediabetes to diabetes","authors":"Yongsheng Zhang ,&nbsp;Wenqi Hu ,&nbsp;Dawei Wang ,&nbsp;Hongyu Zhang ,&nbsp;Guang Zhang","doi":"10.1016/j.jdiacomp.2025.109238","DOIUrl":"10.1016/j.jdiacomp.2025.109238","url":null,"abstract":"<div><h3>Background</h3><div>The atherogenic index of plasma (AIP) is recognized as a robust predictor of cardiovascular outcomes and diabetes incidence. However, no studies have comprehensively investigated the impact of baseline AIP levels and longitudinal AIP trajectories on diabetes progression in patients with prediabetes.</div></div><div><h3>Methods</h3><div>After data inclusion and exclusion, this retrospective cohort study included 16,411 patients with prediabetes undergoing ≥3 health examinations (2019–2024). Latent Class Trajectory Modeling characterized longitudinal AIP trajectory patterns, and Cox proportional-hazards models evaluated associations of baseline AIP quartiles and trajectory groups with diabetes progression.</div></div><div><h3>Results</h3><div>During a mean 4-year follow-up (65,644 person-years), 14.14 % patients with prediabetes (2320) progressed to diabetes. Baseline AIP quartiles showed a graded relationship with diabetes progression risk. Three AIP trajectories were identified: the low plateau trajectory (<em>N</em> = 4422, 26.95 %), the medium decreasing trajectory (<em>N</em> = 8183, 49.86 %), and the high decreasing trajectory (<em>N</em> = 3806, 23.19 %). Compared to the low plateau trajectory, the medium decreasing trajectory, and the high decreasing trajectory exhibited progressively elevated diabetes risk in the fully adjusted model (HR = 1.42, 95 % CI: 1.22–1.65 and HR = 2.26, 95 % CI: 1.81–2.83, respectively).</div></div><div><h3>Conclusion</h3><div>Patients with higher baseline AIP and higher trajectories are associated with higher risks for the progression from prediabetes to diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 2","pages":"Article 109238"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variability in the urinary albumin-to-creatinine ratio predicts mortality in patients with type 2 diabetes","authors":"Jui-Tang Wu ,&nbsp;Yu-Hsuan Li ,&nbsp;Yu-Cheng Cheng ,&nbsp;Kuo-Hsiung Shu ,&nbsp;Junyi Wu ,&nbsp;I-Te Lee","doi":"10.1016/j.jdiacomp.2025.109249","DOIUrl":"10.1016/j.jdiacomp.2025.109249","url":null,"abstract":"<div><h3>Aim</h3><div>To investigate the effects of variability in urinary albumin-to-creatinine ratio (UACR) on mortality in patients with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 3536 patients with T2DM. The annual UACR data were collected not only in the index year but also within two years before the index year to calculate standard deviation (SD). The primary endpoint was all-cause mortality, which was identified by the National Death Registry files from the Ministry of Health and Welfare in Taiwan.</div></div><div><h3>Results</h3><div>During a median follow-up of 49.3 months, 242 (6.8 %) patients died. Among patients with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m², those in the increased UACR with high SD group had the highest hazard ratio (HR) for mortality (3.686; 95 % confidence interval [CI]: 2.116–6.421) compared with those in the normal UACR with low SD group. Similarly, among patients with an eGFR &lt;60 mL/min/1.73m², those in the increased UACR with high SD group had the highest HR for mortality (3.404; 95 % CI: 1.361–8.511) compared with those in the normal UACR with low SD group.</div></div><div><h3>Conclusion</h3><div>UACR variability and increased UACR have a synergistic effect on mortality prediction in patients with T2DM.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 2","pages":"Article 109249"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(26)00006-1","DOIUrl":"10.1016/S1056-8727(26)00006-1","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 2","pages":"Article 109261"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world experience with ranibizumab 0.5 mg initial intensive treatment for diabetic macular edema: 24-week outcomes of the RISING-K study","authors":"Kunho Bae ,&nbsp;Na-Kyung Ryoo ,&nbsp;Yong-Sok Ji ,&nbsp;Jeong Hun Bae ,&nbsp;In Young Chung ,&nbsp;Han Joo Cho ,&nbsp;Junyeop Lee ,&nbsp;Jae Yon Won ,&nbsp;Hyewon Chung ,&nbsp;Younghoon Lee ,&nbsp;Jihyun Park ,&nbsp;Seung-Young Yu","doi":"10.1016/j.jdiacomp.2025.109251","DOIUrl":"10.1016/j.jdiacomp.2025.109251","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy of initial intensive ranibizumab 0.5 mg treatment in Korean patients with diabetic macular edema (DME).</div></div><div><h3>Methods</h3><div>This was a multicenter, observational, retrospective study including patients with DME who received an initial intensive treatment, operationally defined as ≥3 ranibizumab 0.5 mg injections within 4 months (including the first dose). Primary outcome was mean change in best-corrected visual acuity (BCVA) at Week 24. Secondary outcomes were mean change in central subfield thickness (CST), intraretinal (IRF) and subretinal fluid (SRF), and diabetic retinopathy severity score (DRSS). Subgroup analyses evaluated these endpoints according to patients with/without prior anti-vascular endothelial growth factor (VEGF) treatment and by fluid compartment.</div></div><div><h3>Results</h3><div>Of total 83 patients (mean age: 63.4 years), 15 (18.1 %) received prior anti-VEGFs. At Week 24, mean BCVA gain from baseline was 5.1 ± 9.3 letters (<em>p</em> &lt; 0.001), 52.5 % and 13.8 % patients had ≥5 and ≥15 letters gain, respectively. Mean CST reduction from baseline was significant (−99.8 ± 122.1 μm; <em>p</em> &lt; 0.001). DRSS improved in 19.2 % patients. BCVA gain showed higher tendency in eyes with prior anti-VEGF exposure (7.1 vs 4.7 letters; <em>p</em> = 0.0873), whereas CST reduction tended to be greater in treatment-naïve eyes (−106.7 vs −68.3 μm; <em>p</em> = 0.3377. All patients had IRF at baseline which disappeared in 29 % patients after 24 weeks resulting in BCVA improvement. At baseline, 23 % patients had SRF, of which 13 % resolved by Week 24. Patients without SRF at baseline had greater BCVA improvement, while patients with SRF at baseline had greater mean CST reduction.</div></div><div><h3>Conclusion</h3><div>Initial intensive treatment with ranibizumab 0.5 mg was effective in both treatment-naïve and prior-treated patients with DME. Functional outcomes varied by prior anti-VEGF treatment and fluid compartment.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 2","pages":"Article 109251"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}